<DOC>
	<DOCNO>NCT00000803</DOCNO>
	<brief_summary>To determine safety anti-HIV activity delavirdine mesylate ( U-90152 ) combination zidovudine ( AZT ) and/or didanosine ( ddI ) versus AZT/ddI combination . U-90152 demonstrated anti-HIV activity . Since combination drug either AZT ddI synergistic inhibitory activity HIV-1 vitro , triple therapy appear great inhibitory activity HIV-1 vitro dual therapy , use U-90152 combination AZT and/or ddI may improve benefit drug person HIV disease .</brief_summary>
	<brief_title>A Phase II Double-Blind Study Delavirdine Mesylate ( U-90152 ) Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT ddI Combination Therapy</brief_title>
	<detailed_description>U-90152 demonstrate anti-HIV activity . Since combination drug either AZT ddI synergistic inhibitory activity HIV-1 vitro , triple therapy appear great inhibitory activity HIV-1 vitro dual therapy , use U-90152 combination AZT and/or ddI may improve benefit drug person HIV disease . Patients randomized receive U-90152/AZT/ddI , U-90152/AZT , U-90152/ddI , AZT/ddI 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis patient CD4 count &lt; = 200 cells/mm3 . Allowed : Topical antifungal agent . Oral ketoconazole , fluconazole , itraconazole candidiasis disseminate fungal infection . Isoniazid , ethambutol , pyrazinamide , clofazimine , ciprofloxacin , clarithromycin acute maintenance therapy mycobacterial disease ( also clarithromycin MAC prophylaxis ) . Acute maintenance therapy toxoplasmosis . Acute maintenance therapy acyclovir ( 1000 mg/day ) herpes simplex virus infection . rEPO rGCSF . Antibiotics bacterial infection ( except rifampin rifabutin ) . Antipyretics , analgesic , nonsteroidal antiinflammatory agent , antiemetic , methadone . Concurrent Treatment : Allowed cutaneous Kaposi 's sarcoma : Localized radiation therapy . Limited intralesional therapy . Patients must : HIV infection . CD4 count 100 500 cells/mm3 . Prior cumulative monotherapy &lt; = 6 month ( may take either AZT ddI , ) OR prior antiretroviral therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy ( basal squamous cell carcinoma skin , Stage 1 2 cervical intraepithelial neoplasia , minimal Kaposi 's sarcoma ) . Considered unlikely comply study requirement . Concurrent Medication : Excluded : Antiretroviral therapy biologic response modifier ( except study medication , rEPO , rGCSF ) . Rifampin . Rifabutin . Terfenadine . Astemizole . Loratadine . Quinidine . Digitoxin . Systemic corticosteroids 21 consecutive day . Foscarnet . Systemic cytotoxic chemotherapy malignancy . Patients follow prior condition exclude : History intolerance AZT &lt; = 600 mg/day ddI &lt; = 400 mg/day discontinuation either drug toxicity . History intolerance trifluoperazine piperazine citrate ( per amendment ) . History pancreatitis . History grade 2 bad peripheral neuropathy . Unexplained temperature &gt; = 38.5 C 7 day within past 30 day . Chronic diarrhea 15 day past 30 day . Prior Medication : Excluded : Prior foscarnet induction maintenance therapy . Prior U90152 . Prior ddC d4T . Prior AZT/ddI combination take separately different time . Prior nonnucleoside reverse transcriptase inhibitor ( nevirapine , atevirdine , etc. ) . Prior protease inhibitor ( although patient ACTG 282 eligible ) . HIV1 vaccine within past 21 day . Acute treatment serious infection opportunistic infection within past 14 day . Excluded within past 30 day : Interferon interleukin . Rifampin . Rifabutin . Terfenadine . Astemizole . Loratadine . Recombinant EPO GCSF . Hydroxyurea . SPV30 . Any investigational drug . Active drug alcohol use .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>